HEALTH

TyraTech expanding U.S. distribution of its homeopathic lice remedy

BY Michael Johnsen

MELBOURNE, Fla. — TyraTech, a life sciences company focusing on nature-derived insect and parasite control products, recently announced that it has secured product listings for its Vamousse head lice product range, including its Vamousse Treatment mousse and Vamousse Protection shampoo, across Walmart and through Cardinal Health, according to published reports. 
 
In addition to Walmart and Cardinal, Vamousse is available through online retailers Amazon.com, drugstore.com and Walgreens.com. Additionally, the products are now available through extended distribution through McKesson, as well as with independent pharmacy retailers, including Rochester Drug, Lewis Drug and Bartell Drug.
 
"We are extending our distribution network in the USA online and through a network of independent pharmacies," said Bruno Jactel, TyraTech CEO.  
 
TyraTech’s new non-pesticide homeopathic head lice treatment Vamousse will safely kill 100% of head lice and nits within 15 minutes of application, according to the company. The company also is introducing a daily shampoo application to prevent lice infestation, or re-infestation. The mousse will retail for a suggested $24.99, while the preventive shampoo will retail for a suggested $19.99.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Ducere Pharma names Pete Rose Myoflex spokesman

BY Michael Johnsen

PHILADELPHIA — Pete Rose, baseball’s all-time hits leader, is the new spokesperson for the topical muscle, joint and arthritis pain reliever Myoflex, Ducere Pharma announced recently. 
 
“Pete’s a Hall of Famer in our eyes and we are excited to have him on board with Myoflex,” stated Chris Dominello, Ducere Pharma CEO. “He is a legendary player who is known across all generations. The passion and intensity that Pete brought to the game of baseball has inspired many kids of his and future generations to give 110% no matter what they are doing. Pete played the game like no other and Myoflex is a pain reliever like no other.”
 
Rose, also known during his playing days as “Charlie Hustle” because of the reckless abandon he played the game with, will make appearances, appear in advertising and be available for media tours as part of his agreement with Myoflex.
 
“I suffer from a number of aches and pains because of the way I played baseball,” Rose said. “Since starting to use Myoflex, I can already feel a difference. Myoflex is a great product that helps soothe the aches and pains that go along with giving it your all no matter what you do. I am looking forward to working with the great people of Myoflex and Ducere Pharma.”
 
Rose is baseball’s all-time hits leader with 4,256 hits and holds a number of other records. When you combine his desire to win at all costs and his on-field success, this made him one of the most popular baseball players of his generation, Ducere noted. 
 
“When you look at what he meant for the game of baseball, his hustle, grit and determination, you can see why so many kids wanted to be like him and play like him, even as they got older and transitioned into weekend warriors,” Dominello said. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Study in Annals of the Rheumatic Diseases bears out efficacy of Cosamin DS

BY Michael Johnsen

EDGEWOOD, Md. — Nutramax Labs announced Thursday the publication of results from an international clinical study that demonstrates the effectiveness of glucosamine hydrochloride and chondroitin sulfate — the same active ingredients found in the joint health dietary supplement Cosamin DS — in the management of joint health and wellness. The results of the MOVES (Multicentre Osteoarthritis InterVEntion trial with Sysadoa) study are published in the online edition of the peer-reviewed journal, Annals of the Rheumatic Diseases.
 
“The MOVES trial is truly an important study that provides additional evidence to support the use of glucosamine hydrochloride and chondroitin sulfate, at a daily dose of 1,500 and 1,200 milligrams, respectively, in managing joint health in a wide variety of patient populations,” stated Nicholas DiNubile, clinical associate in the Department of Orthopedic Surgery at the Hospital of the University of Pennsylvania. “This new data is especially encouraging for patients, and it reinforces my ongoing approach to long-term joint health management in my practice, particularly for people who are experiencing a significant increase in the incidence of deteriorating joint health yet wish to remain physically active.”
 
Cosamin DS is the most researched glucosamine/chondroitin joint health supplement, Nutramax stated. Cosamin DS uses FCHG49 glucosamine and TRH122 chondroitin sulfate, providing a unique combination of ingredients not found in other glucosamine/chondroitin combination dietary supplements. “I tell my patients, not all supplements are created equal – brand matters. It’s important to recommend supplements supported by extensive research like Cosamin,” DiNubile said.
 
“We were the first company to develop this combination worldwide and publish clinical studies showing its benefits for joint health. We have been conducting both human and veterinary research for over 20 years, so it’s gratifying to see studies of this magnitude that confirm our previous findings. The MOVES study further underscores the value of Cosamin DS as a safe and effective option to support joint health,” said Robert Henderson, chairman Nutramax.
 
MOVES is a multicenter, randomized, parallel-group, double-blind, controlled clinical trial that enrolled 606 patients at 42 centers in France, Germany, Poland and Spain. The study was sponsored by Bioibérica, suppliers of the chondroitin sulfate used in Cosamin DS. The study was developed as an extension of the GAIT (Glucosamine/Chondroitin Arthritis Intervention Trial) study, which showed that the combination of glucosamine hydrochloride (1,500 mg/day) and chondroitin sulfate (1,200 mg/day) was effective in a moderate to severe subgroup of patients.
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?